Planta Med 2012; 78 - CL37
DOI: 10.1055/s-0032-1320272

In a placebo-controlled study ß-Ecdysone (ECD) prevented the development of the metabolic syndrome

D Seidlova-Wuttke 1, W Wuttke 1
  • 1Hormone and Obesity Center, 37081 Bahnhofsallee 1d, Goetttingen, and VerdeVital GmbH 37120 Domaene 6, Bovenden, Germany

Large abdominal fat depots secrete proinflammatory cytokines which lead often to a Metabolic Syndrome. In an open study 200mg Ecd prevented this development. Ecd is produced by spinach and therefore a placebo-controlled trial was performed with an Ecd enriched spinach extract. Daily uptake of 2×50mg Ecd administered with 2×450mg spinach powder in slightly overweight women and men (18 placebo, 21 verum) significantly (p<0.05) reduced bodyweight by 1.3%, waist circumference by 3.1% and total body fat by 7.6% while the amounts of muscles were increased by 2.9%. The serum marker for inflammatory processes, C-reactive protein, was reduced by 38% and this resulted in a reduction of serum cholesterol by 17% and of triglycerides by 37%. It is concluded that this product can be used to treat and prevent the development of the Metabolic Syndrome.